Literature DB >> 7647801

Expression analysis of the ataxin-1 protein in tissues from normal and spinocerebellar ataxia type 1 individuals.

A Servadio1, B Koshy, D Armstrong, B Antalffy, H T Orr, H Y Zoghbi.   

Abstract

Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder caused by expansion of a CAG trinucleotide repeat which codes for glutamine in the protein ataxin-1. We have investigated the effect of this expansion on ataxin-1 by immunoblot analysis. The wild-type protein is detected in both normal and affected individuals; however, a mutant protein which varies in its migration properties according to the size of the CAG repeat is detected in cultured cells and tissues from SCA1 individuals. The protein has a nuclear localization in all normal and SCA1 brain regions examined but a cytoplasmic localization of ataxin-1 was also observed in cerebellar Purkinje cells. Our data show that in SCA1, the expanded alleles are faithfully translated into proteins of apparently normal stability and distribution.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7647801     DOI: 10.1038/ng0595-94

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  72 in total

Review 1.  Polyglutamine pathogenesis.

Authors:  C A Ross; J D Wood; G Schilling; M F Peters; F C Nucifora; J K Cooper; A H Sharp; R L Margolis; D R Borchelt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 2.  The complex clinical and genetic classification of inherited ataxias. I. Dominant ataxias.

Authors:  S Di Donato
Journal:  Ital J Neurol Sci       Date:  1998-12

Review 3.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

Review 4.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

5.  SCA1-like disease in mice expressing wild-type ataxin-1 with a serine to aspartic acid replacement at residue 776.

Authors:  Lisa Duvick; Justin Barnes; Blake Ebner; Smita Agrawal; Michael Andresen; Janghoo Lim; Glenn J Giesler; Huda Y Zoghbi; Harry T Orr
Journal:  Neuron       Date:  2010-09-23       Impact factor: 17.173

6.  Induction of endogenous genes following infection of human endothelial cells with an E1(-) E4(+) adenovirus gene transfer vector.

Authors:  R Ramalingam; S Rafii; S Worgall; N R Hackett; R G Crystal
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Somatic mosaicism of expanded CAG repeats in brains of patients with dentatorubral-pallidoluysian atrophy: cellular population-dependent dynamics of mitotic instability.

Authors:  H Takano; O Onodera; H Takahashi; S Igarashi; M Yamada; M Oyake; T Ikeuchi; R Koide; H Tanaka; K Iwabuchi; S Tsuji
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

8.  Self-assembling vascular endothelial growth factor nanoparticles improve function in spinocerebellar ataxia type 1.

Authors:  Yuan-Shih Hu; Jeehaeh Do; Chandrakanth Reddy Edamakanti; Ameet R Kini; Marco Martina; Samuel I Stupp; Puneet Opal
Journal:  Brain       Date:  2019-02-01       Impact factor: 13.501

9.  Reduction of protein kinase A-mediated phosphorylation of ATXN1-S776 in Purkinje cells delays onset of Ataxia in a SCA1 mouse model.

Authors:  Judit M Pérez Ortiz; Nissa Mollema; Nicholas Toker; Carolyn J Adamski; Brennon O'Callaghan; Lisa Duvick; Jillian Friedrich; Michael A Walters; Jessica Strasser; Jon E Hawkinson; Huda Y Zoghbi; Christine Henzler; Harry T Orr; Sarita Lagalwar
Journal:  Neurobiol Dis       Date:  2018-05-11       Impact factor: 5.996

Review 10.  Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1.

Authors:  Huda Y Zoghbi; Harry T Orr
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.